Danaher’s SCIEX and Molecular Devices Businesses Debut New Products
It has been a busy beginning of the year for Danaher’s Life Sciences segment. In January, the business reported 2020 revenues of $10.6 billion, representing 47% of the total revenues of science and technology conglomerate Danaher. The Life Sciences unit such as biopharmaceuticals and COVID-19 vaccines. In 2020, the pharmaceutical end-market represented approximately 25% of the company’s total revenues, and the majority of Danaher Life Sciences’ sales.
To serve the pharmaceutical end-market, Danaher Life Sciences provides solutions for testing at every stage of a drug’s life cycle, from discovery and development, to clinical testing and manufacturing. Complex biological substances must be thoroughly and continuously analyzed and characterized. Drugs work by interacting with the body’s proteins and cells. Thus, numerous analytical techniques are used to study and optimize these interactions to ensure drug candidates and the final product are effective and safe.
A key analytical technique for studying proteins is mass spectrometry (MS). SCIEX, part of Danaher Life Sciences, is one the largest providers of MS systems. Molecular Devices, also part of Danaher Life Sciences, is a leading supplier cell-analysis instrumentation. Recently, each company made major announcements that add new systems to grow Danaher Life Sciences’ stable of solutions for biopharmaceutical analysis, particularly for biologic drugs, the fastest growing sector of the drug market.